[VIRTUAL] HIGH LEVELS OF CIRCULATING PLASMA CELLS (CPC) ARE AN INDEPENDENT HIGH-RISK FEATURE BUT ARE MODULATED BY MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH NOVEL AGENTS

[VIRTUAL] IMPACT OF GAIN AND AMPLIFICATION OF 1Q IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS RECEIVING CARFILZOMIBBASED TREATMENT IN THE FORTE TRIAL

[VIRTUAL] MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT-GENERATION SEQUENCING (NGS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (NDMM): RESULTS FROM THE FORTE TRIAL

[VIRTUAL] DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN TRANSPLANT- INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FRAILTY SUBGROUP ANALYSIS OF MAIA

[VIRTUAL] PREDICTORS OF EARLY RELAPSE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

[VIRTUAL] TREATMENT EMERGENT PERIPHERAL NEUROPATHY IN THE CASSIOPEIA TRIAL

[VIRTUAL] CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS

[VIRTUAL] TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY

[VIRTUAL] ON-DEMAND PLERIXAFOR FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA: A PRELIMINARY ANALYSIS OF THE OBSERVATIONAL STUDY MOZOBL06877

[VIRTUAL] IXAZOMIB-BASED INDUCTION FOLLOWED BY SINGLE-AGENT IXAZOMIB MAINTENANCE IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: UPDATED RESULTS OF THE EMN10-UNITO TRIAL

[VIRTUAL] DEPTH OF RESPONSE AND RESPONSE KINETICS OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA: IKEMA INTERIM ANALYSIS

[VIRTUAL] RECOVERY OF OCULAR EVENTS WITH LONGER-TERM FOLLOW-UP IN THE DREAMM-2 STUDY OF SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE—SUBGROUP ANALYSIS

[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO PRIOR ALKYLATOR THERAPY—SUBGROUP ANALYSIS